rurioctocog alfa pegol at a glance
Medicine class
Extended half-life recombinant factor VIII replacement
Licensed use
Treatment and prevention of bleeding in haemophilia A from 12 years of age
Administration
Injected into a vein after the powder has been reconstituted; home administration requires appropriate training
Important monitoring
Poor bleeding control may indicate factor VIII inhibitors and requires specialist assessment
What is rurioctocog alfa pegol used for?
Its selected UK licence covers factor VIII replacement in haemophilia A.
Treatment of bleeding in people aged 12 years and over with congenital factor VIII deficiency
Prevention of bleeding in people aged 12 years and over with congenital factor VIII deficiency
How does rurioctocog alfa pegol work?
Haemophilia A results from insufficient factor VIII, a protein needed in the clotting cascade. Rurioctocog alfa pegol temporarily replaces factor VIII so a more effective clot can form. Attached polyethylene glycol slows clearance, extending its half-life compared with its parent molecule, octocog alfa.
How to take rurioctocog alfa pegol
Treatment should be supervised by a haemophilia specialist. The powder is mixed only with the supplied solvent and injected intravenously; self-administration should begin only after suitable training.
Use the supplied reconstitution device and follow the product instructions exactly.
Check that the prepared solution is clear and free from particles or discolouration before use.
Use the prepared solution promptly and do not refrigerate it after mixing.
Record the product name and batch number after each administration.
Do not mix it with other medicines or solvents.
rurioctocog alfa pegol side effects
Common or expected effects
- Headache
- Nausea
- Diarrhoea
- Dizziness
- Rash
- Hives
Get urgent medical advice
- Severe allergic reaction or anaphylaxis, including breathing difficulty, facial or tongue swelling, chest tightness, severe dizziness or collapse
- Factor VIII inhibitors, which may present as persistent bleeding or an unexpectedly poor response to treatment
rurioctocog alfa pegol in pregnancy
Experience with rurioctocog alfa pegol during pregnancy is unavailable, so it should be used only when clearly indicated after specialist assessment. Anyone pregnant or planning pregnancy should involve their haemophilia and obstetric teams because bleeding risks and the baby's potential inheritance require coordinated planning.
rurioctocog alfa pegol while breastfeeding
There is no established experience of its use during breastfeeding. A haemophilia specialist should assess whether treatment is clearly indicated and discuss the uncertainties with the person breastfeeding.
rurioctocog alfa pegol interactions
No interactions between recombinant factor VIII products and other medicines have been reported, but the clinical team should still be told about all medicines being used.
Other medicines or solvents in the same preparation
Compatibility has not been established, so rurioctocog alfa pegol must not be mixed with other medicinal products.
Common questions about rurioctocog alfa pegol
Answers are fully visible for fast scanning and source review.
What is rurioctocog alfa pegol used for?
It replaces missing factor VIII to treat or prevent bleeding in haemophilia A. The selected UK licence covers people aged 12 years and over.
Is rurioctocog alfa pegol a blood product?
It is recombinant factor VIII made using cell-culture biotechnology rather than extracted from donated human plasma.
Why is rurioctocog alfa pegol PEGylated?
Polyethylene glycol is attached to the factor VIII molecule to slow its clearance and extend its half-life compared with octocog alfa.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.